Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid ...

Initial clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in ...
Nasdaq

Immunocore Reports Initial Data from Phase 1/2 Trial of HIV Functional Cure Candidate IMC-M113V at CROI 2025

Immunocore reports positive initial data for HIV treatment candidate IMC-M113V, showing safety and signs of viral control post-treatment. The observation of delayed viral rebound and/or viremia ...
Nasdaq

Solid Biosciences Reports Promising Initial Data from Phase 1/2 INSPIRE DUCHENNE Trial for SGT-003 in Duchenne Muscular Dystrophy

Solid Biosciences has reported promising initial findings from its Phase 1/2 INSPIRE DUCHENNE trial of SGT-003, a gene therapy aimed at treating Duchenne muscular dystrophy. Data from the first three ...
The New England Journal of Medicine

Pulsed Field Ablation as Initial Therapy for Persistent Atrial Fibrillation

Guidelines recommend a trial of antiarrhythmic drugs before catheter ablation for persistent atrial fibrillation. Whether pulsed field ablation (PFA) may be a preferred initial treatment is ...
Hosted on MSN

A fentanyl vaccine enters human trials in 2026 — here's how it works

A vaccine that blocks the effects of fentanyl — including overdose — will enter human trials in the coming months, perhaps leading the way to the first-ever proactive treatment for opioid use disorder ...
Seeking Alpha

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic ...

Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and Decreases in Mutant Z-AAT in Circulation Across ...